


**Amendments To The Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

What is claimed is:

1. (Currently Amended) A compound of formula (I)



wherein:

$R^1$  represents aryl, heteroaryl, -aryl-X-aryl, -aryl-X-heteroaryl, -aryl-X-heterocyclyl, -heteroaryl-X-heteroaryl, -heteroaryl-X-aryl or -heteroaryl-X-heterocyclyl;

wherein said aryl, heteroaryl and heterocyclyl groups of  $R^1$  may be optionally substituted by one or more substituents which may be the same or different, and which are selected from the group consisting of halogen, hydroxy, cyano, nitro, oxo, haloC<sub>1-6</sub> alkyl, polyhaloC<sub>1-6</sub> alkyl, haloC<sub>1-6</sub> alkoxy, polyhaloC<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkylthio, C<sub>1-6</sub> alkoxyC<sub>1-6</sub> alkyl, C<sub>3-7</sub> cycloalkylC<sub>1-6</sub> alkoxy, C<sub>1-6</sub> alkanoyl, C<sub>1-6</sub> alkoxycarbonyl, C<sub>1-6</sub> alkylsulfonyl, C<sub>1-6</sub> alkylsulfinyl, C<sub>1-6</sub> alkylsulfonyloxy, C<sub>1-6</sub> alkylsulfonylC<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkylsulfonamidoC<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkylamidoC<sub>1-6</sub> alkyl, aryl, arylsulfonyl, arylsulfonyloxy, aryloxy, arylsulfonamido, arylcarboxamido, aroyl, -COR<sup>15</sup>, -COOR<sup>15</sup>, NR<sup>15</sup>R<sup>16</sup>, -CONR<sup>15</sup>R<sup>16</sup>, -NR<sup>15</sup>COR<sup>16</sup>, -NR<sup>15</sup>SO<sub>2</sub>R<sup>16</sup>, and -SO<sub>2</sub>NR<sup>15</sup>R<sup>16</sup>, wherein R<sup>15</sup> and R<sup>16</sup> independently represent hydrogen, C<sub>1-6</sub> alkyl, haloC<sub>1-6</sub> alkyl, polyhaloC<sub>1-6</sub> alkyl, or C<sub>3-6</sub> cycloalkyl, or R<sup>15</sup> and R<sup>16</sup> together form a heterocyclic ring;

X represents a bond, O, CO, SO<sub>2</sub>, OCH<sub>2</sub> or CH<sub>2</sub>O;

$R^2$  represents C<sub>3-8</sub> alkyl, C<sub>3-6</sub> alkenyl, C<sub>3-6</sub> alkynyl, C<sub>3-6</sub> cycloalkyl, C<sub>5-6</sub> cycloalkenyl, or -C<sub>1-4</sub>alkyl-C<sub>3-6</sub> cycloalkyl;

wherein said C<sub>3-6</sub> cycloalkyl groups of R<sup>2</sup> may be optionally substituted by one or more substituents which may be the same or different, and which are selected from the group consisting of halogen, C<sub>1-4</sub> alkyl, and trifluoromethyl groups; each R<sup>3</sup> and R<sup>4</sup> group independently represents C<sub>1-4</sub> alkyl; m and n independently represents 0, 1 or 2; p and q independently represent 1 or 2; or a pharmaceutically acceptable salt thereof.

2. (Previously Amended) The compound of formula (I) as defined in claim 1 wherein R<sup>1</sup> represents

-aryl optionally substituted by a cyano, -CONR<sup>15</sup>R<sup>16</sup>, -COR<sup>15</sup>, halogen, or -NR<sup>15</sup>COR<sup>16</sup> group;

-heteroaryl optionally substituted by a cyano, C<sub>1-6</sub> alkyl, polyhaloC<sub>1-6</sub> alkyl, -CONR<sup>15</sup>R<sup>16</sup>, -COR<sup>15</sup>, or -COOR<sup>15</sup> group;

-aryl-X-heterocyclyl;

-aryl-X-heteroaryl optionally substituted by a halogen, C<sub>1-6</sub> alkyl, or aryl group; or

-heteroaryl-X-heterocyclyl.

3. (Previously Amended) The compound of formula (I) as defined in claim 2 wherein R<sup>1</sup> represents

pyrid-3-yl optionally substituted by a -CONR<sup>15</sup>R<sup>16</sup> group,

-phenyl-1,2,4-oxadiazol-5-yl optionally substituted by a C<sub>1-6</sub> alkyl group,

phenyl optionally substituted by a -COR<sup>15</sup> group,

pyridazin-3-yl optionally substituted by a polyhaloC<sub>1-6</sub> alkyl group,

pyrazin-2-yl optionally substituted by a polyhaloC<sub>1-6</sub> alkyl, or

pyrimidin-5-yl optionally substituted by a polyhaloC<sub>1-6</sub> alkyl group.

4. (Previously Amended) The compound of formula (I) as defined in claim 3 wherein R<sup>1</sup> represents

pyrid-3-yl optionally substituted by a 6-CON(H)(Me) or 6-CON(H)(Et) group,

3-methyl-1,2,4-oxadiazol-5-yl, phenyl optionally substituted by a 4-COMe group,  
pyridazin-3-yl optionally substituted by a 6-CF<sub>3</sub> group, or  
pyrimidin-5-yl optionally substituted by a 2-CF<sub>3</sub> group.

5. (Previously Amended) The compound of formula (I) as defined in claim 1 wherein m and n represent 0.
6. (Canceled)
7. (Previously Amended) The compound of formula (I) as defined in claim 1 wherein R<sup>2</sup> represents C<sub>3-8</sub> alkyl, C<sub>3-6</sub> cycloalkyl, or -C<sub>1-4</sub>alkyl-C<sub>3-6</sub> cycloalkyl.
8. (Previously Amended) The compound of formula (I) as defined in claim 7 wherein R<sup>2</sup> represents 1-methylpropyl, isopropyl, cyclobutyl, or -CH<sub>2</sub>-cyclopropyl.
9. (Previously Amended) The compound of formula (I) as defined in claim 8 wherein R<sup>2</sup> represents isopropyl or cyclobutyl.
10. (Previously Amended) The compound as defined in claim 1 which is a compound of formula E1-E120 or a pharmaceutically acceptable salt thereof.
11. (Previously Amended) The compound as defined in claim 1 which is  
1-(1-methylethyl)-4-({1-[4-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]-4-piperidinyl}oxy)piperidine;  
5-{4-[(1-cyclobutyl-4-piperidinyl)oxy]-1-piperidinyl}-N-methyl-2-pyridinecarboxamide;  
1-(4-{4-[(1-cyclobutyl-4-piperidinyl)oxy]-1-piperidinyl}phenyl)ethanone;  
3-{4-[(1-cyclobutyl-4-piperidinyl)oxy]-1-piperidinyl}-6-(trifluoromethyl)pyridazine;  
or  
5-{4-[(1-cyclobutyl-4-piperidinyl)oxy]-1-piperidinyl}-2-(trifluoromethyl)pyrimidine;  
or a pharmaceutically acceptable salt thereof.

12. (Previously Amended) A pharmaceutical composition which comprises the compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.


13. – 15. (Cancelled).

16. (Currently Amended) A method of treatment of neurological diseases which comprises administering to a ~~host~~ human in need thereof an effective amount of a compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable salt thereof.

17. (Cancelled).

18. (Original) A process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof, which process comprises:


(a) reacting a compound of formula (II)



(II)

wherein  $R^2$ ,  $R^3$ ,  $R^4$ ,  $m$ ,  $n$ ,  $p$  and  $q$  are as defined in claim 1, with a compound of formula  $R^1-L^1$ , wherein  $R^1$  is as defined in claim 1 and  $L^1$  represents a suitable leaving group, such as a halogen atom; or

(b) reacting a compound of formula (III)




(III)

wherein  $R^1$ ,  $R^3$ ,  $R^4$ ,  $m$ ,  $n$ ,  $p$  and  $q$  are as defined in claim 1, with a compound of formula  $R^2-L^2$  where  $R^2$  is as defined in claim 1 and  $L^2$  represents a suitable leaving group, such as a halogen atom or a sulfonate such as methanesulfonate; or

(c) reacting a compound of formula (III) as defined above with a compound of formula  $H-R^2=O$  under reductive conditions, wherein  $R^2$  is as defined in claim 1 for  $R^2$  or a group convertible thereto; or

(d) preparing a compound of formula (I) wherein  $p$  represents 1 which comprises reduction of a compound of formula (IV)



(IV)

wherein  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $m$ ,  $n$  and  $q$  are as defined in claim 1 and  $L^{3-}$  represents a suitable counter ion such as a halogen atom; or

(e) deprotecting a compound of formula (I) or converting groups which are protected; and optionally thereafter

(f) interconversion to other compounds of formula (I).